Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M403702200 on August 2, 2004

J. Biol. Chem., Vol. 279, Issue 40, 41998-42007, October 1, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/40/41998    most recent
M403702200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroeder, T. M.
Right arrow Articles by Westendorf, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroeder, T. M.
Right arrow Articles by Westendorf, J. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Histone Deacetylase 3 Interacts with Runx2 to Repress the Osteocalcin Promoter and Regulate Osteoblast Differentiation*

Tania M. Schroeder{ddagger}, Rachel A. Kahler§, Xiaodong Li¶||, and Jennifer J. Westendorf¶||**

From the {ddagger}Graduate Program in Biochemistry, Molecular Biology and Biophysics, and the §Graduate Program in Microbiology, Immunology and Cancer Biology, The Cancer Center, and the ||Department of Orthopaedic Surgery, the University of Minnesota, Minneapolis, Minnesota 55455

Received for publication, April 2, 2004 , and in revised form, July 22, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Runt domain transcription factor Runx2 (AML-3, and Cbfa1) is essential for osteoblast development, differentiation, and bone formation. Runx2 positively or negatively regulates osteoblast gene expression by interacting with a variety of transcription cofactor complexes. In this study, we identified a trichostatin A-sensitive autonomous repression domain in the amino terminus of Runx2. Using a candidate approach, we found that histone deacetylase (HDAC) 3 interacts with the amino terminus of Runx2. In transient transfection assays, HDAC3 repressed Runx2-mediated activation of the osteocalcin promoter. HDAC inhibitors and HDAC3-specific short hairpin RNAs reversed this repression. In vivo, Runx2 and HDAC3 associated with the osteocalcin promoter. These data indicate that HDAC3 regulates Runx2-mediated transcription of osteoblast genes. Suppression of HDAC3 in MC3T3 preosteoblasts by RNA interference accelerated the expression of Runx2 target genes, osteocalcin, osteopontin, and bone sialoprotein but did not significantly alter Runx2 levels. Matrix mineralization also occurred earlier in HDAC3-suppressed cells, but alkaline phosphatase expression was not affected. Thus, HDAC3 regulates osteoblast differentiation and bone formation. Although HDAC3 is likely to affect the activity of multiple proteins in osteoblasts, our data show that it actively regulates the transcriptional activity of the osteoblast master protein, Runx2.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Runx2 is one of three mammalian homologues of the Drosophila protein Runt. Runx2 is required for osteoblast formation and chondrocyte differentiation and thus is an essential regulator of intramembranous and endochondral bone formation (1-3). Runx2 haploinsufficiency causes the autosomal dominant bone disorder cleidocranial dysplasia (4, 5), but elevated Runx2 levels cause osteopenia (6) and contribute to murine T cell lymphomogenesis (7). Furthermore, Runx2 polymorphisms are associated with altered bone mineral density and susceptibility to osteoporotic fractures (8). The sensitivity of osteoblasts to changes in wild-type Runx2 levels provides biological proof that its activity must be tightly controlled. At the molecular level, Runx2 is regulated by transcriptional and translational mechanisms, post-translational modifications, including phosphorylation, and by interactions with other transcription factors and chromatin-modifying enzymes (9-20). Because the Runx DNA-binding element is necessary but not sufficient to activate tissue-specific gene expression (21, 22), it was hypothesized over a decade ago that Runx proteins are promoter organizers (23). It is now apparent that Runx factors indeed interact with other transcription factors as well as recruit both co-activator and co-repressor complexes to promoters. Known co-activators of Runx2 include YAP, HES, and the histone acetyltransferases, p300, CBP, MOZ, and MORF (24-27). The list of Runx2-associating co-repressors includes just TLE, mSin3a, and histone deacetylase (HDAC)1 6 (18, 19, 28, 29); however, among all known transcriptional co-repressors, only a small fraction have been tested for interactions with Runx2. Because Runx2 is crucial for bone formation, we are interested in understanding how its transcriptional activity is affected by co-repressor complexes in osseous cells.

HDACs are enzymatic components of multiprotein complexes that are recruited by transcription factors to specific DNA regulatory sequences. They remove acetyl residues from nucleosomal histones and other substrates leading to chromatin condensation and gene repression (30-34). Eleven mammalian HDACs are classified into two groups on the basis of sequence similarities with yeast proteins. Class I HDACs (HDAC1-3, -8, and -11) are homologues of yeast RPD3 and are widely expressed in the nuclei of mammalian cells (35-37). Class II HDACs (HDAC4 -7, -9, and -10) are similar to yeast Hda1/2 and appear to shuttle between nuclear and cytoplasmic compartments in specific cell types (18, 38-45). Major functions of HDACs are to regulate gene expression, transport ubiquitinated protein aggregates, and deacetylate tubulin (46-48). Global suppression of HDAC activity by chemical inhibitors commonly causes cell cycle arrest and may promote cell differentiation (49, 50).

HDAC3 is one of the better-studied HDACs. It associates with several transcription factors, including GATA1, peroxisome proliferator-activated receptor-{gamma}, retinoblastma protein, thyroid hormone receptor, TEL, and TFII-I (51-55). HDAC3 also interacts with the co-repressors N-CoR and SMRT (53, 56), which link HDAC3 to transcription factors and other co-repressors. HDAC3 is also the crucial catalytic component of several class II HDAC complexes (57, 58). Thus, HDAC3 appears to be a very important factor in multiple co-repressor complexes that regulate gene expression. HDAC3-deficient animals have not been described; however, HDAC3 suppression in HeLa cells by RNA interference blocked cell proliferation and transcriptional repression by thyroid hormone receptor (59, 60).

In this study, we identified HDAC3 as a transcriptional co-repressor of Runx2 using a candidate gene approach. HDAC3 interacted with the amino terminus of Runx2, which acts as an autonomous repression domain on a heterologous promoter. HDAC3 repressed Runx2-induced activation of the osteocalcin promoter and was found associated with the osteocalcin promoter in osteoblasts. Stable suppression of HDAC3 by RNA interference accelerated osteoblast mineralization and the expression of osteoblast differentiation genes. These data identify HDAC3 as a regulator of Runx2 transcriptional activity in osseous cells and suggest that its expression regulates bone formation.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—COS and C2C12 cells were cultured in Dulbecco's modified Eagle medium containing 10% fetal bovine serum (FBS), 200 mM L-glutamine, 50 units/ml of penicillin and 50 µg/ml of streptomycin. CH310T1/2, MC3T3-E1, ROS17/2.8, and UMR-106 were maintained in minimal essential medium (MEM) supplemented with 10% FBS, 1% nonessential amino acids, 200 mM L-glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin. To induce differentiation, confluent MC3T3-E1 cells were cultured in {alpha}-MEM containing 10% FBS, 50 units/ml penicillin, 50 µg/ml streptomycin, 50 µg/ml ascorbic acid, and 10 mM {beta}-glycerolphosphate. The differentiation medium was replaced every 3 days.

Plasmids—The GAL-TK-luciferase (Luc) reporter plasmid and the GAL-Runx2 fusion proteins were previously described (18). Human and mouse HDAC3 mammalian expression vectors were kindly provided by Dr. Edward Seto (Lee Moffit Cancer Center, Tampa, FL) (61). The pSHAG and pSHAG-Firefly luciferase (Ffl) vectors were obtained from Dr. Gregory Hannon (Cold Spring Harbor Laboratories) (62). The pSHAG-HDAC3 short-hairpin RNA vectors were constructed by annealing oligonucleotide pairs (purchased from Integrated DNA Technologies, Inc., Coralville, IA) and subcloning them into the BamHI/BseRI sites of the pSHAG vector. HDAC3 shRNA #1 recognizes bases pairs 681-713 of the murine HDAC3 cDNA. The sequences of its oligonucleotide pair are: 5'-TGCTTGTAACTCTGGTCATCAATGCCATGAAGCTTGATGGTATTGATGATCAGAGTTATAAGCATCTTTTTTT-3' and 5'-GATCAAAAAAAGATGCTTATAACTCTGATCATCAATACCATCAAGCTTCATGGCATTGATGACCAGAGTTACAAGCACG-3'. HDAC3 shRNA #2 recognizes bases pairs 1231-1263 of the murine HDAC3 cDNA. The sequences of its oligonucleotide pair are: 5'-GTCGCCATCATAGAACTCATTGGGTGCTGAAGCTTGAGTATCCGATGAGTTCTATGATGGCGACTATTTTTTT-3' and 5'-GATCAAAAAAATAGTCGCCATCATAGAACTCATCGGATACTCAAGCTTCAGCACCCAATGAGTTCTATGATGGCGACCG-3'.

The self-inactivating (SIN) retrovirus was created from a murine stem cell virus (MSCV) expression plasmid, by removing the XbaI/NheI fragment from the 3' long terminal repeat of the vector, pMSCV-Puro-HpaI-Gateway (a gift from Dr. Gregory Hannon (63)). Short-hairpin RNAs recognizing Ffl or HDAC3 were transferred from pSHAG vectors into the pSIN-MSCV-puro-HpaI-Gateway vector with the Gateway cloning system (Invitrogen). The resulting plasmids are referred to as pSIN-MSCV-Ffl shRNA and pSIN-MSCV-HDAC3 shRNA.

Creation of Stable Cell Lines—Retroviruses were produced as previously described (64). Briefly, 293T cells were co-transfected with 20 µg of pSIN-MSCV-shRNA vector and 20 µg of the helper plasmid pCL2 by calcium phosphate precipitation. At 24 and 48 h, supernatants were collected, passed through a 0.45-µm filter and stored at -80 °C. MC3T3 cells were transduced with 1 ml of viral supernatant in the presence of 8 µg/ml polybrene on two consecutive days. Transduced cells were selected by culturing in the presence of 10 µg/ml puromycin for 3 days.

Antibodies—The polyclonal antibodies recognizing HDAC3 or HDAC4 were purchased from Cell Signaling Technologies (Beverly, MA). The polyclonal anti-Runx2 antibodies, S19 (N terminus) and C19 (C terminus) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The polyclonal anti-AML3 antibody was provided by Dr. Scott Hiebert. The monoclonal anti-HA and polyclonal anti-FLAG antibodies were purchased from Sigma-Aldrich Co. (St. Louis, MO). The monoclonal anti-{beta}-catenin antiserum was purchased from BD Biosciences Transduction Laboratories. The FHOD1 antiserum was previously described (64).

Transcription Assays—COS and C3H10T1/2 cells were transiently transfected with the murine osteocalcin gene 2 (mOG2)-Luc reporter plasmid, pCMV-secreted alkaline phosphatase (SEAP), pCMV-Runx2 and pCMV-FLAG-HDAC3, and pSHAG-shRNA using DEAE-dextran or LipofectAMINE (Invitrogen), respectively. NIH3T3 cells were transfected with the GAL-TK-Luc reporter plasmid and GAL-Runx2 plasmids with Superfect (Qiagen, Valencia, CA). Luciferase activity was measured 40 h post-transfection with a luciferase assay system (Promega, Madison, WI). SEAP activity was measured as previously described (18, 65). Luciferase values were normalized with SEAP values to control for transfection efficiency. The fold changes in activation or repression were calculated relative to samples transfected with mOG2-Luc or GAL-TK-Luc alone. Trichostatin A (TSA, Sigma) and cyclic hydroxamic acid-containing peptide 31 (CHAP31, kindly provided by Minoru Yoshida of The University of Tokyo) were added 24 h post-transfection.

Immunoprecipitations and Immunoblots—ROS17/2.8 cells were lysed on ice by resuspension in ice-cold lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100, 25 mM MG132, and protease inhibitors (Mini Complete protease inhibitor mixture tablets from Roche Applied Science)). After sonication, lysates were precleared by 30-min incubations with prewashed pansorbin cells (Calbiochem-Novabiochem Corp.) at 4 °C and high speed centrifugation. Lysates were then incubated with nonspecific rabbit IgG (Rockland), HDAC3 (Cell Signaling), or Runx2 antibodies (C19, S19, and AML3) as indicated for 16 h at 4 °C. Immune complexes were collected with Protein A-Sepharose beads (Santa Cruz Biotechnology) for 30 min at 4 °C. The beads were washed three times with a buffer containing 50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1% Nonidet P-40, 25 µM MG132, and protease inhibitors (Mini Complete protease inhibitor mixture tablets). Proteins were eluted from the beads by boiling in 2x Laemmli sample buffer for 5 min, resolved by SDS-8% PAGE, transferred to Immobilon P (Millipore, Bedford, MA), and detected by immunoblotting with the indicated antibodies and enhanced chemiluminescence.

COS cells were transfected with pCMV5-M2-Runx2-(1-227) and pCMV5-FLAG-HDAC (HDACs 1-6) using DEAE-dextran. The lysates were harvested and incubated with anti-FLAG M2-agarose affinity beads (Sigma) as previously described (18). After incubation, the beads were washed, and proteins bound to the beads were resolved by SDS-10% PAGE and immunoblotted with anti-GAL (Santa Cruz Biotechnology) or anti-FLAG (Sigma) antibodies.

GST Pull-down Assays—GST and GST-Runx1 or Runx2 fusion proteins were produced in DH5{alpha} Escherichia coli and extracted with a lysis buffer containing 1x phosphate-buffered saline, 0.1% Nonidet P-40, and protease inhibitors (Mini Complete protease inhibitor mixture tablets, Roche Applied Science). Lysates were sonicated on ice and cleared by centrifugation. GST proteins were purified by incubating E. coli lysates with glutathione-Sepharose beads (Amersham Biosciences) for 1 h at 4 °C. HDAC3 proteins were in vitro transcribed and translated in rabbit reticulocyte lysates (Promega) with 35S-labeled amino acids (Tran35S-label, ICN Pharmaceuticals, Inc., Irvine, CA) from pBlue-script-HDAC3 according to the manufacturer's instructions. GST proteins and radiolabeled murine HDAC3 were mixed and incubated for 1 h at 4 °C, washed three times with lysis buffer, resolved by SDS-12% PAGE, and visualized by autoradiography.

Chromatin Immunoprecipitation Assays—The chromatin immunoprecipitation (ChIP) assays were performed in ROS17/2.8 cells as previously reported (66). Briefly, cross-linked lysates were immunoprecipitated with no antibody, anti-HA (12CA5), Runx2 (S19 and C19), or HDAC3 antibodies. An additional control reaction (mock) contained no chromatin or antibody. Nested PCR was performed with primer pairs generated to detect bases encompassing the proximal Runx2 binding site in the rat osteocalcin promoter. External primer pairs for PCR were: 5'-GGATCTTATGGAGGCATTTTC-3' and 5'-CCAAAGGATGCTGTGGTTGG-3'. The internal primer pairs for the nested PCR were: 5'-GAGGCTTTCTTCTTTCAAGTT-3' and 5'-TGGGCAAAGGCCTGGAAGG-3'.

cDNA Synthesis and Reverse Transcription PCR—Total RNA from MC3T3 cells stably expressing Ffl and HDAC3 shRNAs was isolated with TRIzol reagent (Invitrogen). Total RNA (1 µg) was reverse-transcribed to cDNA with the Invitrogen Superscript kit according to its instructions. PCR was performed on the cDNA using primers specific for HDAC3 (5'-CGGGTGCTCTACATTGATATCGACATCCAC-3' and 5'-TACCAGGAGAGGGATATTGAAACTCTTGAC-3'), Runx2 (5'-ATGGATCCATATGCTACCTGCCATCAC-3' and 5'-TAGAATTCATTAAACAGTTGGGGAACT-3'), and actin (5'-GACTTCGAGCAAGAGATGGCCAC-3' and 5'-CAATGCCAGGGTACATGGTGGTG-3').

Quantitative Real-time PCR—cDNA was prepared as described above. Real-time PCR was carried out in a Lightcycler (Roche Diagnostics) using the following primer sets: HDAC3 (5'-CGGGTGCTCTACATTGATATCGACATCCAC-3' and 5'-TACCAGGAGAGGGATATTGAAACTCTTGAC-3'), osteocalcin (5'-CTCTGTCTCTCTGACCTCACAG-3' and 5'-GGAGCTGCTGTGACATCCATAC-3'), osteopontin (5'-TGACCCATCTCAGAAGCAG-3' and 5'-GCTGACTTGACTCATGGCT-3'), bone sialoprotein (5'-GAAACGGTTTCCAGTCCAG-3' and 5'-CTGCATCTCCAGCCTTCTT-3'), and actin (5'-AAGGAAGGCTGGAAAAGAGC-3' and 5'-GCTACAGCTTCACCACCACA-3'). HDAC3, osteopontin, bone sialoprotein, and actin were amplified by adding 1 µl of cDNA diluted 1:10 to the PCR mixture (19 µl) containing each of the primers (0.5 µM), 1.25 mM MgCl2, and 10 µl of the SYBR Green Taq ReadyMix (Sigma-Aldrich Co.). The enzyme was activated at 95 °C for 5 min prior to the start of cycling. The PCR program contained 40 cycles of denaturation at 94 °C for 10 s, annealing of the primers at 56 °C for 10 s, and elongation at 72 °C for 10 s. Osteocalcin and actin were amplified by adding 2 µl of cDNA diluted 1:10 to the PCR mixture (18 µl) containing each of the primers (0.5 µM), 0.05 mg/ml bovine serum albumin, and 10 µl of the Platinum SYBR Green qPCR Supermix uracil glycosylase (Invitrogen). Prior to cycling, the reactions were preincubated at 50 °C for 2 min for decontamination of dU-containing DNA by UDG, then at 95 °C to inactivate UDG and activate Taq. The PCR program was the same as described above. For all reactions, the temperature change rate was 20 C°/s for denaturation, annealing, and elongation. Fluorescence was measured at channel F1 at the end of each elongation cycle. Relative quantification of gene expression was determined by using the 2-{Delta}{Delta}CT method where fold change in gene expression is relative to Day 0 Ffl shRNA samples (67). All samples were normalized to actin.

Differentiation Assays—To assess alkaline phosphatase production, differentiating MC3T3-E1 cells were stained at the indicated times in a buffer containing 100 mM Tris, 100 mM NaCl, 50 mM MgCl2, 337.5 mg/ml nitroblue tetrazolium, and 175 mg/ml 5-bromo-4-chloro-3-indolyl phosphate tolidium salt. Ca2+ accumulation in the matrix was detected by staining the differentiating cell cultures with 40 mM Alizarin Red for 10 min (LabChem Inc., Pittsburgh, PA), washing with distilled water and developing in phosphate-buffered saline.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
The Amino Terminus of Runx2 Acts as an Autonomous Repression Domain That Is Sensitive to the HDAC Inhibitor, TSA—We previously showed that Runx2 contains multiple repression domains (18). That report focused on a potent repression domain in the Runx2 carboxyl terminus (encompassing amino acids 383-513 of the MRIPV isoform), which interacts with TLE and HDAC6. We also showed that a truncated Runx2 protein (residues 1-383) lacking these repression domains suppressed transcription, albeit at lower levels. To identify the repression domain(s) within the first 383 residues of Runx2, we fused various Runx2 sequences to the GAL4 DNA binding domain (GAL) (Fig. 1B). NIH3T3 cells were transiently transfected with the GAL-Runx2 constructs and a reporter, GALTK-Luc, containing four GAL binding sites (Fig. 1A). Similar to our previously published results, GAL-Runx2-(1-513) repressed the promoter 6.2-fold, and GAL-Runx2-(1-383) repressed it 13.7-fold (Fig. 1C). Three Runx2 proteins ((1-327), (1-250), and (1-227)) lacking the activation domain also repressed transcription by 10.6-, 3.8-, and 3.3-fold, respectively. A GAL-Runx2 protein (321-383) containing just the Runx2 transactivation domain did not repress transcription (data not shown). These data demonstrate that Runx2 contains an autonomous repression domain within its amino terminus.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 1.
The amino terminus of Runx2 contains a repression domain that is sensitive to the HDAC inhibitor, TSA. A, schematic of the GAL-TK-Luc reporter plasmid that was used in these experiments. B, left: a diagram of GAL-Runx2 fusion proteins that we constructed for these studies. Right: immunoblot showing expression of the GAL-Runx2 fusion proteins. COS cells were transfected with the GAL-Runx2 fusion protein expression plasmids. Lysates were collected 40 h post-transfection and immunoblotted with an anti-Gal monoclonal antibody. RuntD, Runt domain; AD, activation domain. C, the amino terminus of Runx2 contains autonomous repression domains. NIH3T3 cells were transfected in triplicate with GAL-TK-Luc (1 µg) and CMV-SEAP (1 µg) reporter plasmids and expression plasmids for GAL (1 µg) or GAL-Runx2 fusion proteins (1 µg). Luciferase activity was measured 40 h post-transfection. The fold repression is relative to GAL alone, and the transfection efficiency is normalized using SEAP activity. D, the histone deacetylase inhibitor, TSA, reduces Runx2-dependent repression. The transfections and luciferase assays were performed as described in C except Me2SO (gray bars) or 300 nM TSA (black bars) was added to the samples 24 h post-transfection.

 
To determine if HDAC activity is involved in the repression by the amino terminus of Runx2, the HDAC inhibitor, trichostatin A (TSA), was added to the transcription assays (Fig. 1D). TSA partially inhibited the repression of Runx2-(1-383) and Runx2-(1-327), but completely reversed repression by Runx2-(1-250). These results suggest that an HDAC complex interacts with the first 250 residues of the Runx2 and contributes to Runx2-mediated transcriptional repression; however, HDAC-independent mechanisms also contribute to Runx2-mediated repression.

Runx2 Interacts with HDAC3—We used a candidate approach to identify HDACs that may interact with the amino terminus of Runx2. COS cells were co-transfected with pCMV5-GAL-Runx2-(1-227) and pCMV-FLAG-HDAC 1, 2, 3, 4, 5, or 6. GAL-Runx2-(1-227) was used because it repressed as well as GAL-Runx2-(1-250) in repression assays (Fig. 1C) and was more stable than GAL-Runx2-(1-250) (Fig. 1B). Whole cell extracts were immunoprecipitated with anti-FLAG-conjugated agarose beads. The immunoprecipitates and a fraction of the whole cell extracts were separated by SDS-PAGE and immunoblotted with anti-GAL and anti-FLAG antibodies. GALRunx2-(1-227) was only present in the HDAC3 and HDAC4 immune complexes (Fig. 2). Although more Runx2 appears to interact with HDAC3 complexes than with HDAC4 complexes, it is important to note that there is significantly less GALRunx2-(1-227) protein in the lysates of cells expressing HDAC4. In fact, all the HDACs tested, with the exception of HDAC3, blocked the expression of the GAL-Runx2 fusion protein. This likely occurs because the HDACs repress transcription from the CMV intermediate early promoter,2, and therefore in this experiment FLAG-HDACs are suppressing their own ectopic expression as well as that of GAL-Runx2. These results are informative and crucial for the interpretation of functional studies of HDACs described later in this report (see Fig. 4). These data show that HDAC3 does not suppress Runx2 activity by decreasing Runx2 levels. HDAC4, on the other hand, does suppress ectopic Runx2 expression. This limited our exploration of the HDAC4 interaction, because our functional assays utilize a CMV promoter to drive Runx2 expression.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 2.
HDAC3 interacts with the amino terminus of Runx2. A, HDAC3 interacts with the first 227 amino acids of Runx2 (MRIPV isoform) in vivo. COS cells were transfected with GAL-Runx2-(1-227) (3 µg) and the indicated CMV-FLAG-HDAC construct (3 µg). Lysates were collected at 40 h post-transfection and immunoprecipitated with anti-FLAG mAb-conjugated Sepharose beads. Whole cell lysates and immunoprecipitates were immunoblotted with antibodies recognizing GAL (top) and FLAG (bottom) epitopes. The asterisk is adjacent to HDAC3, which is partially hidden by the Runx2-(1-227) protein in lane 4. B, HDAC3 interacts with the Runx2 amino terminus in vitro. Upper panel, GST-Runx2 fusion proteins were incubated with 35S-labeled HDAC3. Proteins complexes were washed and separated by SDS-PAGE. HDAC3 was detected by autoradiography. The GST-(50-179) and GST-(50-179, L148D) fusion proteins contain sequences from the runt domain of Runx 1 (AML-1A). Lower panel, Coomassie staining of GST fusion proteins used in the upper panel. Asterisks indicate the appropriate full-length protein.

 



View larger version (27K):
[in this window]
[in a new window]
  		FIG. 4.
HDAC3 represses Runx2-mediated activation of the osteocalcin promoter. A, HDAC3 represses Runx2-transcriptional activation. COS cells were transfected with the reporter plasmids, mOG2-Luc (0.2 µg) and CMV-SEAP (0.5 µg), and mammalian expression vectors for Runx2 (MRIPV isoform) (1 µg) and HDAC3 (at indicated concentrations). Luciferase activity was determined 40 h after transfection. The fold activation is relative to mOG2-Luc alone, and transfection efficiency is normalized using SEAP activity. B, HDAC3 repression of Runx2 is sensitive to HDAC inhibitors, TSA and CHAP31. The transfection and luciferase assays were performed in C3H10T1/2 cells as described in A except the mammalian expression vector for Runx2 (MASNS isoform) was used, 1 µg of HDAC3 was transfected and TSA or CHAP31 were added at the indicated concentrations 24 h post-transfection.

 
To gain a better understanding of the roles that HDAC3 and HDAC4 may play in regulating Runx2 in osteoblasts, we performed immunoblots on protein extracts from preosteoblastic MC3T3 cells, the myogenic/osteoblast progenitor cell line, C2C12, and two rat osteosarcoma cells lines, ROS17/2.8 and UMR-106. HDAC3 was detected in each of the cell lines, but HDAC4 was detectable only in UMR-106 osteosarcoma cells (Fig. 3A). All of these cells lines express Runx2 (data not shown). Osteocalcin mRNA was detectable in at low levels in MC3T3 (see Fig. 7E) and at higher levels in the ROS17/2.6 cells, but not in the UMR-106 or C2C12 cells (data not shown). Because HDAC3 was more broadly expressed than HDAC4 in this panel of cells, we decided to focus on its role in regulating Runx2 more closely for the rest of this study. Using immunoprecipitates from the rat osteosarcoma cell line ROS17/2.8, we ascertained that full-length Runx2 interacts with HDAC3 in vivo (Fig. 3B). HDAC3 was present in three Runx2 immune complexes that were collected with antibodies recognizing distinct epitopes of Runx2 (Fig. 3B), as well as in the HDAC3 immune complexes. HDAC3 was not present in the control immunoprecipitates. Together these data demonstrate that HDAC3 interacts with Runx2 in vivo.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 3.
Runx2 and HDAC3 interact in osteoblasts. A, osteoblast cell lines express HDAC3. Whole cell lysates (100 µg) were prepared from MC3T3, C2C12, ROS17/2.8, and UMR-106 cells and immunoblotted with the indicated antibodies. B, Runx2 and HDAC3 interact in osteosarcoma cells. A whole cell lysate was prepared from ROS17/2.8 cells, divided into five tubes (~4 mg/tube), and immunoprecipitated with no antibody (-), nonspecific (Control), HDAC3, or Runx2 (C19, S19, and AML3) antibodies. The whole cell lysate (100 µg) and immunoprecipitates were immunoblotted with anti-HDAC3.

 



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 7.
HDAC3 accelerates later stages of osteoblast differentiation. A, stable suppression of HDAC3 by RNA interference in MC3T3 cells. Whole cell lysates (75 µg) were prepared from undifferentiated MC3T3 cells stably expressing Ffl or HDAC3 shRNAs and immunoblotted with HDAC3 and {beta}-catenin antibodies. B, HDAC3 suppression does not alter Runx2 expression in stable MC3T3 cell lines. Reverse transcription-PCR was performed on RNA collected from undifferentiated MC3T3 cells stably expressing Ffl or HDAC3 shRNAs. PCR was performed using primers recognizing the indicated cDNA. C, HDAC3 suppression does not alter alkaline phosphatase expression. MC3T3 cells stably expressing Ffl and HDAC3 shRNAs were differentiated in the presence of ascorbic acid and {beta}-glycerol phosphate. Alkaline phosphatase staining was performed on the indicated days. D, HDAC3 suppression accelerates Ca2+ accumulation in the matrix. Alizarin red staining was performed on differentiating MC3T3 cells on the indicated days. E, HDAC3 suppression accelerates osteocalcin, osteopontin, and bone sialoprotein expression. Real-time PCR was performed on cDNA from differentiated MC3T3 cells stably expressing either Ffl or shRNA #1 on the indicated days. Gray bars represent Ffl shRNA-expressing cells, and black bars represent HDAC3 shRNA-expressing cells, the asterisk indicates a p value of <0.05, between Ffl and HDAC3 shRNA cells at that time point, as determined by unpaired t testing.

 
We further mapped the interaction domain of Runx2 with HDAC3 with in vitro pull-down experiments. Approximately equal amounts of recombinant GST-Runx fusion proteins (Fig. 2B, lower panel) or GST alone were incubated with in vitro transcribed and translated HDAC3. HDAC3 interacted with the GST-Runx2 proteins containing the amino-terminal residues (Fig. 2B, upper panel). These included GST-Runx2-(1-117), GST-Runx2-(1-227), and GST-Runx2-(1-327). In contrast, HDAC3 did not interact with GST, GST-Runx2-(94-327), or GST-Runx2-(321-513). These data indicate that the extreme amino terminus (residues 1-117) of Runx2 is necessary and sufficient for the interaction with HDAC3. The runt domain (RuntD) of Runx2 is 93% identical to the RuntD of Runx1. Durst et al. (68) recently demonstrated that HDAC3 interacts with Runx1. To determine if HDAC3 interacts with this highly conserved domain, GST-Runx1-(50-179) or GST-Runx1-(50-179, L148D) were incubated with HDAC3-expressing reticulocyte lysates. The L148D mutation disrupts DNA binding (69). Neither interacted with HDAC3 (Fig. 2B); thus RuntD does not contribute significantly to the interaction between Runx proteins and HDAC3.

HDAC3 Represses Runx2-dependent Activation of the Osteocalcin Promoter—The functional significance of the Runx2-HDAC3 interaction was determined by testing the effects of HDAC3 on Runx2 transcriptional activity. The osteocalcin promoter is a well characterized target of Runx proteins and contains three binding sites for Runx2 (70, 71). COS cells were transiently transfected with an osteocalcin reporter plasmid (mOG2-luc) (72) and mammalian vectors expressing Runx2 and HDAC3. Cell lysates were collected, and luciferase assays were performed. Consistent with previous results from our laboratory and others, Runx2 (MRIPV isoform) activated the bone-specific osteocalcin promoter by 7.5-fold (Fig. 4A) (1, 73, 74). Similarly, the longer Runx2 isoform (MASNSL) activated the osteocalcin promoter by 11.5-fold (Fig. 4B, lane 6). HDAC3 did not effect the basal activity of the osteocalcin promoter but inhibited Runx2-dependent activation of this promoter in a concentration-dependent manner (Fig. 4, A and B). The repression was sensitive to the HDAC inhibitors, TSA and CHAP31 (Fig. 4B). These inhibitors modestly increased the basal activity of the promoter (lanes 1-5) and Runx2-dependent activation (lanes 6-8). Importantly, both inhibitors completely reversed HDAC3-mediated repression of Runx2 activity (lanes 12-15); although, high concentrations of CHAP31 (100 nM) were slightly toxic. These data demonstrate that HDAC activity is required for HDAC3-mediated repression of Runx2.

To confirm that HDAC3 is required for the repression, shRNAs that suppress HDAC3 expression by RNA interference were added to the transcription assays. We created four shRNAs for the murine HDAC3 cDNA and subcloned them into the pSHAG vector. In transient expression assays, only one shRNA (denoted here as #1) suppressed HDAC3 levels in COS7 cells (Fig. 5A). A second shRNA (#2) that did not affect HDAC3 levels was used as a control for these experiments. In the absence of any HDAC3 shRNAs, Runx2 (MRIPV isoform) activated the osteocalcin promoter 8-fold, and HDAC3 blocked this activation as previously shown (Fig. 5B, top). Addition of HDAC3 shRNA #1 prevented HDAC3-mediated repression of Runx2 (Fig. 5B, middle). In contrast, HDAC3 shRNA #2, which does not suppress HDAC3 expression, did not reverse HDAC3-mediated repression (Fig. 5B, bottom). Together these data demonstrate that HDAC3 represses Runx2-dependent activation of the osteocalcin promoter.



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 5.
Suppression of HDAC3 by RNA interference prevents HDAC3-mediated repression of Runx2 activity. A, HDAC3 shRNA #1 suppresses HDAC3 expression. COS cells were transiently transfected with pCMV-HDAC3 and pSHAG-HDAC3 shRNA-vectors #1 or #2. Lysates were collected, separated by SDS-PAGE, and immunoblotted with HDAC3 or {beta}-catenin antibodies (loading control). B, HDAC3 suppression relieves HDAC3 repression of Runx2 activity. These assays were performed as described in Fig. 4A except pSHAG-HDAC3 (1 µg) vectors were added. Cells were transfected with no HDAC3 shRNA (top panel), shRNA#1 (middle), or shRNA#2 (bottom).

 
HDAC3 Associates with the Osteocalcin Promoter—Having determined that HDAC3 is expressed in osteoblasts, binds to Runx2, and represses Runx2-dependent activation of the osteocalcin promoter, we next asked if HDAC3 is associated with the osteocalcin promoter in vivo. To examine this, chromatin immunoprecipitation (ChIP) experiments were performed in ROS17/2.8 cells. Cross-linked and fragmented DNA-protein complexes were immunoprecipitated with either no antibody, anti-HA antibodies, Runx2 antibodies (S19 or C19), or anti-HDAC3 antibodies. Nested PCR analysis on purified DNA was performed with primers that span the proximal Runx2 binding site in the osteocalcin promoter. As shown in Fig. 6, osteocalcin promoter DNA was amplified in samples collected with Runx2 or HDAC3 antibodies (Fig. 6). There was little or no amplification in the mock sample (no chromatin input) and samples collected with beads alone (no antibody) or the anti-HA antibodies (nonspecific control). These data demonstrate that HDAC3 can interact with the region of the osteocalcin promoter containing a Runx2 binding site in ROS17/2.8 cells. Together with our data showing that HDAC3 interacts with Runx2 and represses Runx2-dependent transcription of the osteocalcin promoter, these results suggest that HDAC3 may modulate osteocalcin expression.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 6.
HDAC3 associates with the osteocalcin promoter. ChIP assays demonstrate that HDAC3 interacts with the osteocalcin promoter. ROS17/2.8 cells were cross-linked with formaldehyde, washed, lysed, and immunoprecipitated with no antibody, nonspecific (anti-HA), Runx2 (S19 and C19), or HDAC3 antibodies. Two rounds of PCR were performed using nested primers that encompass the proximal Runx2 binding site within the osteocalcin promoter. Lanes 1 and 2 are PCR controls, lanes 3-5 are negative controls for ChIP, and lanes 6-8 are test samples.

 
HDAC3 Suppression Accelerates Osteoblast Differentiation—To determine the functional significance of HDAC3 on osteoblast differentiation, HDAC3 expression was suppressed in MC3T3 cells using RNA interference. The HDAC3 shRNAs were placed into a pSIN-MSCV-Puro vector and stably introduced into MC3T3 cells by retroviral transduction. HDAC3 protein levels in MC3T3 cells expressing shRNA #1 were less than 50% of those in cells expressing Ffl shRNA (Fig. 7A). HDAC3 mRNA levels were down-regulated by ~5-fold in undifferentiated MC3T3 cells (Fig. 7, B and E) and remained low in differentiating populations. Runx2 mRNA levels were unchanged (Fig. 7B). We did not observe any drastic changes in cell proliferation or growth as a result of this level of HDAC3 suppression (data not shown). We also did not observe any changes in the levels of a double strand RNA response gene (oligoadenylate synthetase 1) as a result of shRNA production (data not shown). When the MC3T3 cells expressing shRNAs for HDAC3 or Ffl were placed in an in vitro differentiation assay, no gross changes in the rate of alkaline phosphatase production, which is a relatively early marker of osteoblast differentiation, were seen (Fig. 7C). In contrast, matrix mineralization and nodule formation occurred 2-3 days earlier in HDAC3-suppressed cells as compared with control cells (Fig. 7D). To determine whether genes that are both regulated by Runx2 and involved in mineralization were also expressed earlier in HDAC3-suppressed cells, we collected RNA at time points up to the onset of mineralization (day 6) and performed quantitative PCR. HDAC3 expression in MC3T3 cells containing shRNA #1 was down-regulated at day 0 and remained suppressed at days 4 and 6. Consistent with our ChIP and functional assays, osteocalcin mRNA was increased at day 4 in HDAC3-suppressed cells relative to MC3T3 cells expressing Ffl shRNA (Fig. 7E). Low levels of osteocalcin transcripts were detected in undifferentiated cells. By day 6, osteocalcin transcripts were expressed at equal levels in the control and HDAC3-suppressed cells. Relatively similar results were seen with osteopontin and bone sialoprotein, although bone sialoprotein transcripts were not detected in undifferentiated cells (75, 76). Thus, HDAC3 suppression accelerates osteoblast mineralization and the expression of various genes that are up-regulated during osteoblast differentiation. These data suggest that HDAC3 plays a role in regulating the timing of osteoblast differentiation, perhaps by directly regulating Runx2 activity.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In this report, we demonstrate that HDAC3 regulates Runx2 trans-activity and contributes to in vitro osteoblast mineralization. Our studies show that HDAC3 interacts with the amino terminus of Runx2 to regulate osteoblast-specific gene expression. A physical interaction between Runx2 and HDAC3 was demonstrated in vivo using co-immunoprecipitation. Functional interactions between these proteins were also observed in in vitro transcription assays. Additional studies indicated that Runx2 and HDAC3 co-localize to similar subnuclear structures (data not shown). We mapped the interaction to the amino-terminal 117 residues of Runx2, which contains an autonomous repression domain. To date, HDAC3 is the first protein shown to interact with the amino terminus of Runx2. Our biochemical studies were performed with the Runx2 isoform beginning with amino acids MRIPV; however, functional studies demonstrated that HDAC3 represses this isoform as well as the alternative isoform starting with residues MASNSL (Fig. 4B). Thus HDAC3 can regulate both major Runx2 isoforms. The region of the Runx2 amino terminus that is shared by both isoforms contains a glutamine-alanine (QA) repeat region (residues 35-80). It is possible that the QA domain contributes to interactions with HDAC3. However, Runx1 also interacts with HDAC3 but does not contain a QA-rich region (68). Further structural and functional examinations of this domain will be important, because it is altered in a small percentage of cleidocranial dysplasia patients and in individuals with varying bone densities (5, 8).

HDAC3 repressed Runx2-dependent activation of the osteocalcin promoter in transiently transfected cells. This repression was sensitive to the HDAC inhibitors, TSA and CHAP31. In addition, the activity was specific to HDAC3, because shRNAs directed against HDAC3 eliminated the repression. Previous studies implicated histone acetyltransferases in activation of the osteocalcin promoter (26) and described the amino terminus, including the QA-rich region, as an activation domain in the context of the entire protein but not autonomously (77). This is the first study to identify a HDAC as a co-repressor of the osteocalcin promoter. Our results may indicate that the activity of this region depends on interactions with specific cofactors. Moreover, these studies support the hypothesis that chromatin remodeling is essential for the regulation of the osteocalcin promoter (78, 79). The one or more signals that switch Runx2 from an activator to a repressor remain to be identified. An interesting possibility is that cellular signaling cascades targeting Runx2 (80) will affect its interactions with co-repressors. Runx2 is a phosphoprotein (80), and phosphorylation of specific residues may dictate interactions with cofactor complexes. Phosphorylation of JNK and c-Jun relieve interactions between c-Jun- and HDAC3-containing repression complexes (81). Because the AP-1 complex cooperates with Runx2 to activate osteoblast genes (20, 82), it is also a strong candidate to indirectly regulate HDAC3 interactions with Runx2. Of interest, Imai and colleagues (83) recently demonstrated that interactions between mSin3A and Runx1 (AML1) are relieved by Runx1 phosphorylation. The serine residues that are modified to control mSin3a interactions are conserved in Runx2. Current studies in our laboratory are focusing on their roles in regulating the interactions between Runx2 and co-repressors, including HDAC3.

Although mammalian Runt domain proteins are best known for their ability to activate gene expression, their Drosophila homologue Runt was originally described as a transcriptional repressor (84). Within the last 3 years, the underappreciated repression capabilities of mammalian Runt domain proteins have been identified and numerous mechanisms of repression reported. Runt domain proteins interact with a variety of transcriptional co-repressors to regulate gene expression (18, 28). Each family member interacts with the Groucho/TLE and mSin3A proteins (28). Runx1 interacts with at least six HDACs (68). We have shown that Runx2 interacts with HDAC3, HDAC6, and possibly HDAC4 (this report and Ref. 18). It remains to be conclusively determined if these co-repressor proteins interact with Runx factors as part of unique or shared co-repressor complexes. It is appreciated that HDACs are the enzymatic components of large multiprotein complexes that interact with many transcription factors. HDAC3 complexes contain nuclear receptor co-repressors, SMRT and N-CoR (53, 56). It was also reported that HDAC3 is the required enzymatic component of complexes containing Class II HDACs, HDAC4, -5, and -7 (57, 58). Interactions between HDAC3 and Class II HDACs (e.g. HDAC6) were not addressed in these studies. Our work indicates that HDAC3 and HDAC6 bind to distinct regions of Runx2. Our data also indicate that their expression patterns are different in that HDAC3 is strictly nuclear and expressed throughout osteoblast differentiation (data not shown), whereas HDAC6 shuttles from cytoplasm to the nucleus and is up-regulated during late stages of differentiation (18). Therefore, we currently favor the hypothesis that HDAC3 and HDAC6 regulate Runx2 activities in different contexts. Although it is almost certain that Runx2 repressor complexes contain many co-repressors, more work needs to be done to define the spatial and temporal organization of these complex components during osteoblast differentiation.

The physical and functional relationships between Runx2 and HDAC3 may be important for regulating bone formation. HDAC3 is expressed in C2C12 cells, which have osteogenic potential upon BMP2 stimulation, MC3T3 preosteoblasts, and two osteosarcoma cell lines. Suppression of HDAC3 by RNA interference in MC3T3 cells caused early expression of osteocalcin, osteopontin, and bone sialoprotein, and consequently accelerated a late stage event in osteoblast differentiation, namely calcium deposition in the mineralizing matrix. An earlier marker of osteoblast maturation, alkaline phosphatase production, was not affected by HDAC3 suppression. Interestingly, the dissociation of HDAC3 from peroxisome proliferator-activated receptor-{gamma}-retinoblastma protein complexes by retinoblastma protein phosphorylation in adipocytes stimulated their differentiation (52). Thus, HDAC3 may be a broad regulator of cellular maturation and terminal differentiation. Of note, general suppression of HDAC activity in tumor cells facilitates their differentiation, and several small molecule HDAC inhibitors are in phase I or II clinical trials (49, 50). Our data showing that HDAC3 binds the osteocalcin promoter and directly regulates the activity of Runx2 suggests that HDAC3 may play a crucial role in regulating osteoblast differentiation. These results suggest that suppressing HDAC3 activity may be a mechanism of increasing bone formation.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grants AR48147 and AR050938, The V Foundation for Cancer Research, and The Cancer Center at the University of Minnesota. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

** To whom correspondence should be addressed: The Cancer Center, University of Minnesota, MMC 806, 420 Delaware St. SE, Minneapolis, MN 55455. Tel.: 612-626-3365; Fax: 612-626-4915; E-mail: weste047{at}umn.edu.

1 The abbreviations used are: HDAC, histone deacetylase; FBS, fetal bovine serum; MEM, minimal essential medium; Ffl, firefly luciferase; SIN, self-inactivating; MSCV, murine stem cell virus; shRNA, short hairpin RNA; HA, hemagglutinin; mOG2, murine osteocalcin gene 2; CMV, cytomegalovirus; SEAP, secreted alkaline phosphatase; TSA, trichostatin A; CHAP31, cyclic hydroxamic acid-containing peptide 31; GST, glutathione S-transferase; ChIP, chromatin immunoprecipitation. Back

2 J. J. Westendorf, unpublished data. Back


   ACKNOWLEDGMENTS
 
We thank Drs. Scott Hiebert, Edward Seto, Gregory Hannon, and Yoshido Minuro for kindly providing antibodies, expression plasmids, and reagents. We also thank Drs. Andre van Wijnen and Soraya Gutierrez Gallegos for helpful discussions and technical assistance.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997) Cell 89, 747-754[CrossRef][Medline] [Order article via Infotrieve]
  2. Enomoto, H., Enomoto-Iwamoto, M., Iwamoto, M., Nomura, S., Hiemeno, M., Kitamura, Y., Kishimoto, T., and Komori, T. (2000) J. Biol. Chem. 275, 8695-8702[Abstract/Free Full Text]
  3. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y. H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S., and Kishimoto, T. (1997) Cell 89, 755-764[CrossRef][Medline] [Order article via Infotrieve]
  4. Mundlos, S., Otto, F., Mundlos, C., Mulliken, J. B., Aylsworth, A. S., Albright, S., Lindhout, D., Cole, W. G., Henn, W., Knoll, J. H., Owen, M. J., Mertelsmann, R., Zabel, B. U., and Olsen, B. R. (1997) Cell 89, 773-779[CrossRef][Medline] [Order article via Infotrieve]
  5. Otto, F., Kanegane, H., and Mundlos, S. (2002) Hum. Mutat. 19, 209-216[CrossRef][Medline] [Order article via Infotrieve]
  6. Vaillant, F., Blyth, K., Andrew, L., Neil, J. C., and Cameron, E. R. (2002) J. Immunol. 169, 2866-2874[Abstract/Free Full Text]
  7. Blyth, K., Terry, A., Mackay, N., Valliant, F., Bell, M., Cameron, E. R., Neil, J. C., and Stewart, M. (2001) Oncogene 20, 295-302[CrossRef][Medline] [Order article via Infotrieve]
  8. Vaughan, T., Pasco, J. A., Kotowicz, M. A., Nicholson, G. C., and Morrison, N. A. (2002) J. Bone Miner. Res. 17, 1527-1534[CrossRef][Medline] [Order article via Infotrieve]
  9. Drissi, H., Luc, Q., Shakoori, R., Chuva De Sousa Lopes, S., Choi, J. Y., Terry, A., Hu, M., Jones, S., Neil, J. C., Lian, J. B., Stein, J. L., van Wijnen, A. J., and Stein, G. S. (2000) J. Cell. Physiol. 184, 341-350[CrossRef][Medline] [Order article via Infotrieve]
  10. Tou, L., Quibria, N., and Alexander, J. M. (2003) Mol. Cell. Endocrinol. 205, 121-129[CrossRef][Medline] [Order article via Infotrieve]
  11. Lee, K. S., Hong, S. H., and Bae, S. C. (2002) Oncogene 21, 7156-7163[CrossRef][Medline] [Order article via Infotrieve]
  12. Xiao, Z., Simpson, L., and Quarles, L. (2003) J. Cell. Biochem. 88, 493-505[CrossRef][Medline] [Order article via Infotrieve]
  13. Sudhakar, S., Li, Y., Katz, M., and Elango, N. (2001) Biochem. Biophys. Res. Commun. 289, 616-622[CrossRef][Medline] [Order article via Infotrieve]
  14. Xiao, G., Jhang, D., Thomas, P., Benson, M. D., Guan, K., Karsenty, G., and Franceschi, R. T. (2000) J. Biol. Chem. 275, 4453-4459[Abstract/Free Full Text]
  15. Xiao, G., Jhang, D., Gopalakrishnan, R., and Franceschi, R. T. (2002) J. Biol. Chem. 277, 36181-36187[Abstract/Free Full Text]
  16. Wee, H., Huang, J. G., Shigesada, K., and Ito, Y. (2002) EMBO J. 3, 967-974[CrossRef]
  17. Tintut, Y., Parham, F., Le, V., Karsenty, G., and Demer, L. L. (1999) J. Biol. Chem. 274, 28875-28879[Abstract/Free Full Text]
  18. Westendorf, J. J., Zaidi, S. K., Cascino, J. E., Kahler, R., van Wijnen, A. J., Lian, J. B., Yoshida, M., Stein, G. S., and Li, X. (2002) Mol. Cell. Biol. 22, 7982-7992[Abstract/Free Full Text]
  19. Lutterbach, B., Westendorf, J. J., Linggi, B., Isaac, S., Seto, E., and Hiebert, S. W. (2000) J. Biol. Chem. 275, 651-656[Abstract/Free Full Text]
  20. D'Alonzo, R., Selvamurugan, C. N., Karsenty, G., and Partridge, N. C. (2002) J. Biol. Chem. 277, 816-822[Abstract/Free Full Text]
  21. Redondo, J. M., Pfohl, J. L., Hernandez-Munain, C., Wang, S., Speck, N. A., and Krangel, M. S. (1992) Mol. Cell. Biol. 12, 4817-4823[Abstract/Free Full Text]
  22. Meyers, S., Downing, J. R., and Hiebert, S. W. (1993) Mol. Cell. Biol. 13, 6336-6345[Abstract/Free Full Text]
  23. Wang, S. W., and Speck, N. A. (1992) Mol. Cell. Biol. 12, 89-102[Abstract/Free Full Text]
  24. Yagi, R., Chen, L. F., Shigesda, K., Murakami, Y., and Ito, Y. (1999) EMBO J. 18, 2551-2562[CrossRef][Medline] [Order article via Infotrieve]
  25. McLarren, K., Lo, W. R., Grbavec, D., Thirunavukkarasu, K., Karsenty, G., and Stifani, S. (2000) J. Biol. Chem. 275, 530-538[Abstract/Free Full Text]
  26. Sierra, J., Villagra, A., Paredes, R., Cruzat, F., Gutierrez, S., Javed, A., Arriagada, G., Olate, J., Imschenetzky, M., Van Wijnen, A. J., Lian, J. B., Stein, G. S., Stein, J. L., and Montecino, M., (2003) Mol. Cell. Biol. 23, 3339-3351[Abstract/Free Full Text]
  27. Pelletier, N., Champagne, N., Stifani, S., and Yang, X. J. (2002) Oncogene 21, 2729-2740[CrossRef][Medline] [Order article via Infotrieve]
  28. Javed, A., Guo, B., Hiebert, S., Choi, J., Green, J., Zhao, S., Osborne, M. A., Stifani, S., Stein, J. L., Lian, J. B., van Wijnen, A. J., and Stein, G. S. (2000) J. Cell Sci. 113, 2221-2231[Abstract]
  29. Levanon, D., Goldstein, R. E., Bernstein, Y., Tang, H., Goldenberg, D., Stifani, S., Paroush, Z., and Groner, Y. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11590-11595[Abstract/Free Full Text]
  30. Narlikar, G., Fan, J. H., and Kingston, R. E. (2002) Cell 108, 475-487[CrossRef][Medline] [Order article via Infotrieve]
  31. Hassig, C. A., and Schreiber, S. L. (1997) Curr. Opin. Chem. Biol. 1, 300-308[CrossRef][Medline] [Order article via Infotrieve]
  32. Grunstein, M. (1997) Nature 389, 349-352[CrossRef][Medline] [Order article via Infotrieve]
  33. Hong, L., Schroth, G. P., Matthews, H. R., Yau, P., and Bradbury, E. M. (1993) J. Biol. Chem. 268, 305-314[Abstract/Free Full Text]
  34. Lee, D. Y., Hayes, J. J., Pruss, D., and Wolfe, A. P. (1993) Cell 72, 73-84[CrossRef][Medline] [Order article via Infotrieve]
  35. Gray, S. G., and Eckstrom, T. J. (2001) Exp. Cell Res. 262, 75-83[CrossRef][Medline] [Order article via Infotrieve]
  36. Gao, L., Cueto, M. A., Asselbergs, F., and Atadja, P. (2002) J. Biol. Chem. 277, 25748-25755[Abstract/Free Full Text]
  37. Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G. F., Johanson, K., Sung, C. M., Liu, R., and Winkler, J. (2000) J. Biol. Chem. 275, 15254-15264[Abstract/Free Full Text]
  38. Wang, A. H., Bertos, N. R., Vezmar, M., Pelletier, N., Crosato, M., Heng, H. H., Th'ng, J., Han, J., and Yang, X.-J. (1999) Mol. Cell. Biol. 19, 7816-7827[Abstract/Free Full Text]
  39. Bertos, N. R., Wang, A. H., and Yang, X. J. (2001) Biochem. Cell Biol. 79, 243-252[CrossRef][Medline] [Order article via Infotrieve]
  40. Kao, H.-Y., Downes, M., Ordentlich, P., and Evans, R. M. (2000) Genes Dev. 14, 55-66[Abstract/Free Full Text]
  41. Fischle, W., Kiermer, V., Dequiedt, F., and Verdin, E. (2001) Biochem. Cell Biol. 79, 337-348[CrossRef][Medline] [Order article via Infotrieve]
  42. Guardiola, A. R., and Yao, T. P. (2001) J. Biol. Chem. 277, 3350-3356[Medline] [Order article via Infotrieve]
  43. Grozinger, C. M., and Schreiber, S. L. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 4868-4873[Abstract/Free Full Text]
  44. Grozinger, C. M., and Schreiber, S. L. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7835-7840[Abstract/Free Full Text]
  45. Verdel, A., Curtet, S., Brocard, M. P., Rousseaux, S., Lemercier, C., Yoshida, M., and Khochbin, S. (2000) Curr. Biol. 10, 747-749[CrossRef][Medline] [Order article via Infotrieve]
  46. Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., and Yao, T. P. (2003) Cell 115, 727-738[CrossRef][Medline] [Order article via Infotrieve]
  47. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X. F., and Yao, T. P. (2002) Nature 417, 455-458[CrossRef][Medline] [Order article via Infotrieve]
  48. Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin-Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., Horinouchi, S., and Yoshida, M. (2002) EMBO J. 21, 6820-6831[CrossRef][Medline] [Order article via Infotrieve]
  49. Kouraklis, G., and Theocharis, S. (2002) Curr. Med. Chem. Anti-Canc. Agents 2, 477-484[CrossRef]
  50. Rosato, R. R., and Grant, S. (2003) Cancer Biol. Ther. 2, 30-37[Medline] [Order article via Infotrieve]
  51. Ozawa, Y., Towatari, M., Tsuzuki, S., Hayakawa, F., Maeda, T., Miyata, Y., Tanimoto, M., and Saito, H. (2001) Blood 98, 2116-2153[Abstract/Free Full Text]
  52. Fajas, L., Egler, V., Reiter, R., Hansen, J., Kristiansen, K., Debril, M. B., Miard, S., and Auwerx, J. (2002) Dev. Cell 3, 903-910[CrossRef][Medline] [Order article via Infotrieve]
  53. Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J. M., Qin, J., and Wong, J. (2000) EMBO J. 19, 4342-4350[CrossRef][Medline] [Order article via Infotrieve]
  54. Wang, L., and Hiebert, S. W. (2001) Oncogene 20, 3716-3725[CrossRef][Medline] [Order article via Infotrieve]
  55. Wen Y. D., Cress, W. D., Roy, A. L., and Seto, E. (2003) J. Biol. Chem. 278, 1841-1847[Abstract/Free Full Text]
  56. Guenther, M., Barak, G. O., and Lazar, M. A. (2001) Mol. Cell. Biol. 21, 6091-6101[Abstract/Free Full Text]
  57. Fischle, W., Dequiedt, F., Fillon, M., Hendzel, M. J., Voelter, W., and Verdin, E. (2001) J. Biol. Chem. 276, 5826-5835
  58. Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., and Verdin, E. (2002) Mol. Cell 9, 45-57[CrossRef][Medline] [Order article via Infotrieve]
  59. Glaser, K., Li, B. J., Staver, M. J., Wei, R.Q., Albert, D. H., and Davidsen, S. K. (2003) Biochem. Biophys. Res. Commun. 310, 529-536[CrossRef][Medline] [Order article via Infotrieve]
  60. Ishizuka, T., and Lazar, M. A. (2003) Mol. Cell. Biol. 23, 5122-5131[Abstract/Free Full Text]
  61. Yang, W.-M., Yao, Y.-L., Sun, J.-M., Davie, J. R., and Seto, E. (1997) J. Biol. Chem. 272, 28001-28007[Abstract/Free Full Text]
  62. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., and Conklin, D. S. (2002) Genes Dev. 16, 948-958[Abstract/Free Full Text]
  63. Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J., and Lowe, S. W. (2003) Nature 33, 396-400
  64. Koka, S., Neudauer, C. L., Li, X., Lewis, R. E., McCarthy, J. B., and Westendorf, J. J., (2003) J. Cell Sci. 116, 1745-1755[Abstract/Free Full Text]
  65. Berger, J., Hauber, J., Hauber, R., Geiger, R., and Cullen, B. R. (1988) Gene (Amst.) 66, 1-10[CrossRef][Medline] [Order article via Infotrieve]
  66. Shen, J., Montecino, M., Lian, J. B., Stein, G. S., van Wijnen, A. J., and Stein, J. L. (2002) J. Biol. Chem. 277, 20284-20292[Abstract/Free Full Text]
  67. Livak, K. J., and Schmittgen, T. D. (2001) Methods 25, 402-408[CrossRef][Medline] [Order article via Infotrieve]
  68. Durst, K., Lutterbach, L. B., Kummalue, T., Friedman, A. D., and Hiebert, S. W. (2003) Mol. Cell. Biol. 23, 607-619[Abstract/Free Full Text]
  69. Lenny, N., Meyers, S., and Hiebert, S. W. (1995) Oncogene 11, 1761-1769[Medline] [Order article via Infotrieve]
  70. Geoffroy, V., Ducy, P., and Karsenty, G. (1995) J. Biol. Chem. 270, 30973-30979[Abstract/Free Full Text]
  71. Merriman, H. L., van Wijnen, A. J., Hiebert, S., Bidwell, J. P., Fey, E., Lian, J., Stein, J., and Stein, G. S. (1995) Biochemistry 34, 13125-13132[CrossRef][Medline] [Order article via Infotrieve]
  72. Ducy, P., and Karsenty, G. (1995) Mol. Cell. Biol. 15, 1858-1869[Abstract]
  73. Banerjee, C., Hiebert, S. W., Stein, J. L., Lian, J. B., and Stein, G. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4968-4973[Abstract/Free Full Text]
  74. Kahler, R. A., and Westendorf, J. J. (2003) J. Biol. Chem. 278, 11937-11944[Abstract/Free Full Text]
  75. Sato, M., Morii, E., Komori, T., Kawahata, H., Sugimoto, M., Terai, K., Shimizu, H., Yasui, T., Ogihara, H., Yasui, N., Ochi, T., Kitamura, Y., Ito, Y., and Nomura, S. (1998) Oncogene 17, 1517-1525[CrossRef][Medline] [Order article via Infotrieve]
  76. Javed, A., Barnes, G. L., Jasanya, B. O., Stein, J. L., Gerstenfeld, L., Lian, J. B., and Stein, G. S. (2001) Mol. Cell. Biol. 21, 2891-2905[Abstract/Free Full Text]
  77. Thirunavukkarasu, K., Mahajan, M., McLarren, K. W., Stifani, S., and Karsenty, G. (1998) Mol. Cell. Biol. 18, 4197-4208[Abstract/Free Full Text]
  78. Montecino, M., Lian, J., Stein, G., and Stein, J. (1996) Biochemistry 35, 5093-5102[CrossRef][Medline] [Order article via Infotrieve]
  79. Gutierrez, J., Sierra, J., Medina, R., Puchi, M., Imschenetzky, M., van Wijnen, A., Lian, J., Stein, G., Stein, J., and Montecino, M. (2000) Biochemistry 39, 13565-13574[CrossRef][Medline] [Order article via Infotrieve]
  80. Franceschi, R. T., and Xiao, G. (2003) J. Cell. Biochem. 88, 446-454[CrossRef][Medline] [Order article via Infotrieve]
  81. Weiss, C., Schneider, S., Wagner, E. F., Zhang, X., Seto, E., and Bohmann, D. (2003) EMBO J. 22, 3686-3695[CrossRef][Medline] [Order article via Infotrieve]
  82. Hess, J., Porte, D., Munz, C., and Angel, P. (2001) J. Biol. Chem. 276, 20029-20038[Abstract/Free Full Text]
  83. Imai, Y., Kurokawa, M., Yamaguchi, Y., Izutsu, K., Nittta, E., Mitani, K., Satake, M., Noda, T., Ito, Y., and Hirai, H. (2004) Mol. Cell. Biol. 24, 1033-1043[Abstract/Free Full Text]
  84. Manoukian, A. S., and Krause, H. M. (1993) Development 118, 785-796[Abstract]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B.-C. Jeong, Y.-S. Lee, Y.-Y. Park, I.-H. Bae, D.-K. Kim, S.-H. Koo, H.-R. Choi, S.-H. Kim, R. T. Franceschi, J.-T. Koh, et al.
The Orphan Nuclear Receptor Estrogen Receptor-related Receptor {gamma} Negatively Regulates BMP2-induced Osteoblast Differentiation and Bone Formation
J. Biol. Chem., May 22, 2009; 284(21): 14211 - 14218.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Flowers, N. G. Nagl Jr., G. R. Beck Jr., and E. Moran
Antagonistic Roles for BRM and BRG1 SWI/SNF Complexes in Differentiation
J. Biol. Chem., April 10, 2009; 284(15): 10067 - 10075.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. D. Jensen, R. Gopalakrishnan, and J. J. Westendorf
Bone Morphogenic Protein 2 Activates Protein Kinase D to Regulate Histone Deacetylase 7 Localization and Repression of Runx2
J. Biol. Chem., January 23, 2009; 284(4): 2225 - 2234.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. Tanaka, H. Sato, H. Doi, C. A. Yoshida, T. Shimizu, H. Matsui, M. Yamazaki, H. Akiyama, K. Kawai-Kowase, T. Iso, et al.
Runx2 Represses Myocardin-Mediated Differentiation and Facilitates Osteogenic Conversion of Vascular Smooth Muscle Cells
Mol. Cell. Biol., February 1, 2008; 28(3): 1147 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Lamour, C. Detry, C. Sanchez, Y. Henrotin, V. Castronovo, and A. Bellahcene
Runx2- and Histone Deacetylase 3-mediated Repression Is Relieved in Differentiating Human Osteoblast Cells to Allow High Bone Sialoprotein Expression
J. Biol. Chem., December 14, 2007; 282(50): 36240 - 36249.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Villagra, N. Ulloa, X. Zhang, Z. Yuan, E. Sotomayor, and E. Seto
Histone Deacetylase 3 Down-regulates Cholesterol Synthesis through Repression of Lanosterol Synthase Gene Expression
J. Biol. Chem., December 7, 2007; 282(49): 35457 - 35470.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. H. Huh, J.-H. Ryu, and J.-S. Chun
Regulation of Type II Collagen Expression by Histone Deacetylase in Articular Chondrocytes
J. Biol. Chem., June 8, 2007; 282(23): 17123 - 17131.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Gregoire, L. Xiao, J. Nie, X. Zhang, M. Xu, J. Li, J. Wong, E. Seto, and X.-J. Yang
Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2
Mol. Cell. Biol., February 15, 2007; 27(4): 1280 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J. Tolar, A. J. Nauta, M. J. Osborn, A. Panoskaltsis Mortari, R. T. McElmurry, S. Bell, L. Xia, N. Zhou, M. Riddle, T. M. Schroeder, et al.
Sarcoma Derived from Cultured Mesenchymal Stem Cells
Stem Cells, February 1, 2007; 25(2): 371 - 379.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. W. Lee, J. H. Suh, A Y. Kim, Y. S. Lee, S. Y. Park, and J. B. Kim
Histone Deacetylase 1-Mediated Histone Modification Regulates Osteoblast Differentiation
Mol. Endocrinol., October 1, 2006; 20(10): 2432 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E.-J. Jeon, K.-Y. Lee, N.-S. Choi, M.-H. Lee, H.-N. Kim, Y.-H. Jin, H.-M. Ryoo, J.-Y. Choi, M. Yoshida, N. Nishino, et al.
Bone Morphogenetic Protein-2 Stimulates Runx2 Acetylation
J. Biol. Chem., June 16, 2006; 281(24): 16502 - 16511.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Dong, W. Lutz, T. M. Schroeder, L. A. Bachman, J. J. Westendorf, R. Kumar, and M. D. Griffin
Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter
PNAS, November 1, 2005; 102(44): 16007 - 16012.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Javed, G. L. Barnes, J. Pratap, T. Antkowiak, L. C. Gerstenfeld, A. J. van Wijnen, J. L. Stein, J. B. Lian, and G. S. Stein
Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo
PNAS, February 1, 2005; 102(5): 1454 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C.-j. Liu, E. Chang, J. Yu, C. S. Carlson, L. Prazak, X.-P. Yu, B. Ding, P. Lengyel, and P. E. D. Cesare
The Interferon-inducible p204 Protein Acts as a Transcriptional Coactivator of Cbfa1 and Enhances Osteoblast Differentiation
J. Biol. Chem., January 28, 2005; 280(4): 2788 - 2796.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
E. Seeman and G. J. Strewler
Clinical and Basic Research Papers - September and October 2004 Selections
IBMS BoneKEy, November 1, 2004; 1(11): 1 - 5.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/40/41998    most recent
M403702200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroeder, T. M.
Right arrow Articles by Westendorf, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroeder, T. M.
Right arrow Articles by Westendorf, J. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement